Reading BBLG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BBLG free→Reading BBLG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BBLG free→QuarterlyIQ Insights · BBLG
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On March 13, 2026, Bone Biologics Corporation (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) w ith the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s “at the market offering” program for the offer and sale of up to $1,064,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), from time to time through H.C. Wainwright & Co., LLC (“Wainright”), as sales agent, pursuant to the Company’s…
Entry Into a Material Definitive Agreement. On June 27, 2025, Bone Biologics Corporation (the “Company”) priced a public offering (the “Offering”) of (i) 793,750 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), together with Series D warrants (the “Series D Warrants”) to purchase 793,750 shares of Common Stock and Series E warrants (the “Series E Warrants,” together with the Series D Warrants, the “Warrants”) to purchase 793,750 shares of Common Stoc…
Other Events. On June 6, 2025, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached as Exhibit 99.1 to this report. Forward-Looking Statements Certain statements contained in this report, including, without limitation, statements regarding the timing, implementation, and success of the Reverse Stock Split, as well as statements containing the words “expect,” “will,” and words of similar import, constitute “forward-looking statements” w…
Material Modification to Rights of Security Holders. On June 5, 2025, Bone Biologics Corporation (the “Company”) filed a Certificate of Amendment to amend its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware. The Certificate of Amendment effects a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-6 shares, effective as of 12:01 a.m. Easte…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 30, 2025, at an annual meeting of stockholders (the “Annual Meeting”) of Bone Biologics Corporation (the “Company”), the stockholders of the Company approved the Second Amendment (the “Plan Amendment”) to the Company’s 2015 Equity Incentive Plan (the “Plan”) to increase the number of shares of common stock, par value $0.001 per share (“commo…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 7, 2025, Bone Biologics Corporation (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum…
Importance-ranked changes since the prior daily snapshot.
Signal changed from 'None' to 'mixed'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.